Medicines Australia CEO Questions Proposed Tariffs As PM Prepares for China Visit
- Medicines Australia CEO questions Trump’s proposed drug tariffs.
- The European Court rules Russia responsible for MH17 disaster.
- Businesses optimistic about PM Albanese’s upcoming China visit.
Tariff Uncertainty Looms Over Australian Pharmaceuticals
Medicines Australia CEO Elizabeth de Somer shared her concerns recently regarding Donald Trump’s proposed 200% tariffs on pharmaceuticals. During an interview on ABC RN, de Somer emphasized that, at least for now, it remains uncertain if these tariffs will ever be implemented. She stated, “Everybody’s waiting to see what will be made public” following the investigation led by US Commerce Secretary Howard Lutnick, which aims to clarify the rationale behind these proposed tariffs on pharmaceuticals.
Court Rules Russia Accountable for MH17 Tragedy
In related news, the European Court of Human Rights recently ruled that Russia was responsible for the downing of Malaysia Airlines Flight MH17. This tragic event occurred in 2014, resulting in the death of all 298 individuals on board, including 38 Australians. The court found that Russia’s armed forces acted unlawfully by using a missile system supplied to eastern Ukraine, and noted that no steps were taken to distinguish military from civilian aircraft—further widening the scope of their failure to adhere to international law.
Optimism Grows for Trade Relations with China
Transitioning back to domestic affairs, Australian businesses expressed cautious optimism about Prime Minister Anthony Albanese’s upcoming visit to China, a move intended to improve relations between the two nations. Albanese’s six-day trip includes stops in Beijing, Shanghai, and Chengdu, where he will be joined by a delegation of Australian business leaders. David Olsson, president of the Australia China Business Council, mentioned that while there’s hope for a recovery in relations, the situation remains delicate, requiring careful management of risks amid shifting political and economic landscapes.
In summary, the uncertain fate of Donald Trump’s proposed pharmaceutical tariffs has raised concerns among Medicines Australia executives, while the recent verdict from the European Court of Human Rights holds Russia accountable for the MH17 incident. Meanwhile, Australian businesses are cautiously hopeful about the potential benefits of Prime Minister Albanese’s imminent visit to China, which could breathe new life into trade relations. These stories reflect broader implications for both international relations and the local economy.
